Gilead’s Kite Expands Cell Therapy Facilities in US, Europe
The company has leased and purchased facilities in the United States and Europe to expand its cell therapy pipeline.
On May 15, 2018, Gilead Sciences’ Kite Pharma announced that it has leased and purchased new facilities in the United States and Europe to expand its cell therapy pipeline.
The 117,000-square-foot leased facility in Hoofddorp, the Netherlands will engineer and produce cell therapies, including axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy that is currently under review by the European Medicines Agency and was approved by FDA as Yescarta in October 2017. The facility is expected to be fully operational in 2020 and will create more than 300 jobs.
In the US, Kite purchased a new building in Santa Monica, CA, from Astellas Pharma in April 2018 that will be used for cell therapy research, development, and the expansion of clinical manufacturing capabilities. Kite has also leased a 26,000-square-foot facility in Gaithersburg, MD, to support the work of a new cooperative research and development agreement with the National Cancer Institute to develop adoptive cell therapies targeting patient-specific tumor neoantigens. Neoantigens are mutations found on the surface of cancer cells that are unique to each person and tumor, offering the potential for more targeted antitumor activity, according to Gilead.
Source: Gilead Sciences
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
